These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 23737188

  • 1. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.
    Al-Mansour Z, Nelson BP, Evens AM.
    Curr Hematol Malig Rep; 2013 Sep; 8(3):173-83. PubMed ID: 23737188
    [Abstract] [Full Text] [Related]

  • 2. Post-transplant lymphoproliferative disorders.
    Singavi AK, Harrington AM, Fenske TS.
    Cancer Treat Res; 2015 Sep; 165():305-27. PubMed ID: 25655616
    [Abstract] [Full Text] [Related]

  • 3. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
    Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI.
    Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
    [Abstract] [Full Text] [Related]

  • 4. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
    Jagadeesh D, Woda BA, Draper J, Evens AM.
    Curr Treat Options Oncol; 2012 Mar; 13(1):122-36. PubMed ID: 22241590
    [Abstract] [Full Text] [Related]

  • 5. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice.
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [Abstract] [Full Text] [Related]

  • 6. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH, Russ GR, Coates PT.
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [Abstract] [Full Text] [Related]

  • 7. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M, Granai M, Bonzheim I, Steinhilber J, Schittenhelm J, Bethge W, Quintanilla-Martinez L, Fend F, Federmann B.
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [Abstract] [Full Text] [Related]

  • 8. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
    Ranganathan S, Webber S, Ahuja S, Jaffe R.
    Pediatr Dev Pathol; 2004 Jun; 7(4):348-60. PubMed ID: 14564542
    [Abstract] [Full Text] [Related]

  • 9. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
    Chen DB, Song QJ, Chen YX, Chen YH, Shen DH.
    Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
    [Abstract] [Full Text] [Related]

  • 10. Post-transplant lymphoproliferative disorders.
    Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S.
    Nat Rev Dis Primers; 2016 Jan 28; 2():15088. PubMed ID: 27189056
    [Abstract] [Full Text] [Related]

  • 11. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB, Wang Y, Song QJ, Shen DH.
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep 28; 41(9):607-12. PubMed ID: 23157829
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL, Marcus R, Bradley JA.
    Crit Rev Oncol Hematol; 2005 Oct 28; 56(1):155-67. PubMed ID: 15979320
    [Abstract] [Full Text] [Related]

  • 13. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
    Végso G, Hajdu M, Sebestyén A.
    Pathol Oncol Res; 2011 Sep 28; 17(3):443-54. PubMed ID: 21193979
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders.
    Nalesnik MA.
    Recent Results Cancer Res; 2002 Sep 28; 159():9-18. PubMed ID: 11785849
    [Abstract] [Full Text] [Related]

  • 15. Posttransplant lymphoproliferative disorder.
    Everly MJ, Bloom RD, Tsai DE, Trofe J.
    Ann Pharmacother; 2007 Nov 28; 41(11):1850-8. PubMed ID: 17940127
    [Abstract] [Full Text] [Related]

  • 16. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ, Perrine SP, Faller DV.
    Transpl Infect Dis; 2001 Sep 28; 3(3):177-85. PubMed ID: 11493400
    [Abstract] [Full Text] [Related]

  • 17. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
    Choi JH, Park BB, Suh C, Won JH, Lee WS, Shin HJ.
    J Korean Med Sci; 2010 Apr 28; 25(4):523-6. PubMed ID: 20357991
    [Abstract] [Full Text] [Related]

  • 18. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder.
    Lam JKP, Azzi T, Hui KF, Wong AMG, McHugh D, Caduff N, Chan KH, Münz C, Chiang AKS.
    Front Immunol; 2020 Apr 28; 11():1231. PubMed ID: 32625211
    [Abstract] [Full Text] [Related]

  • 19. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, Hariharan S.
    Clin Transplant; 2003 Oct 28; 17(5):417-22. PubMed ID: 14703923
    [Abstract] [Full Text] [Related]

  • 20. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation.
    Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ.
    Transpl Int; 2007 Mar 28; 20(3):207-18. PubMed ID: 17291214
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.